Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System decreased its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 14.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,866 shares of the company’s stock after selling 4,114 shares during the period. New York State Teachers Retirement System’s holdings in Amphastar Pharmaceuticals were worth $1,158,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. GAMMA Investing LLC increased its stake in Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after buying an additional 273 shares during the period. Crossmark Global Holdings Inc. increased its stake in Amphastar Pharmaceuticals by 2.5% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company’s stock valued at $452,000 after buying an additional 275 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Amphastar Pharmaceuticals by 20.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after buying an additional 301 shares during the period. Blue Trust Inc. increased its stake in Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after buying an additional 309 shares during the period. Finally, nVerses Capital LLC increased its stake in Amphastar Pharmaceuticals by 18.2% during the 3rd quarter. nVerses Capital LLC now owns 2,600 shares of the company’s stock valued at $126,000 after buying an additional 400 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 7,426 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $386,523.30. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at $4,898,061.15. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 7,426 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $386,523.30. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at $4,898,061.15. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Yakob Liawatidewi sold 5,214 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the sale, the executive vice president now owns 74,938 shares of the company’s stock, valued at $3,900,522.90. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,741 shares of company stock worth $1,727,262 over the last ninety days. 27.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

AMPH has been the topic of several recent research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler lowered their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $63.00.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $48.31 on Friday. Amphastar Pharmaceuticals, Inc. has a one year low of $36.56 and a one year high of $65.92. The company has a 50-day moving average of $48.44 and a two-hundred day moving average of $44.21. The stock has a market cap of $2.35 billion, a price-to-earnings ratio of 16.10, a PEG ratio of 1.02 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.52 and a quick ratio of 2.63.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.75 by $0.10. The business had revenue of $182.39 million during the quarter, compared to analysts’ expectations of $171.29 million. Amphastar Pharmaceuticals had a net margin of 21.80% and a return on equity of 26.96%. On average, equities research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.67 earnings per share for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.